Daxor CSO granted 25,000 DXR shares

Feldschuh Jonathan Adam reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Feldschuh Jonathan Adam reported acquisition or exercise transactions in this Form 4 filing.

DAXOR CORP Chief Scientific Officer Jonathan Adam Feldschuh received an equity grant of 25,000 shares of Daxor common stock. The shares were granted at a price of $0.00 per share as a stock award rather than an open-market purchase.

According to the filing, Feldschuh now holds a total of 78,908 Daxor common shares directly after this award. A footnote states that the 25,000 granted shares vest on June 23, 2026, meaning they become fully earned on that date if applicable conditions are met.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Feldschuh Jonathan Adam

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Daxor Common Stock	25,000	$0.00	$0.00

Holdings After Transaction: Daxor Common Stock — 78,908 shares (Direct)

Footnotes (1)

1. F1. 25,000 shares granted vest on June 23, 2026.

Key Figures

Shares granted: 25,000 shares Grant price: $0.00 per share Total shares after transaction: 78,908 shares +1 more

4 metrics

Shares granted 25,000 shares Stock award to CSO on June 23, 2026 vesting schedule noted

Grant price $0.00 per share Equity compensation grant, not open-market purchase

Total shares after transaction 78,908 shares Direct holdings of Jonathan Adam Feldschuh following the grant

Vesting date June 23, 2026 25,000 granted shares vest on this date per footnote

Key Terms

Grant, award, or other acquisition, Form 4, vest

3 terms

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

vest financial

"25,000 shares granted vest on June 23, 2026."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DAXOR CORP (DXR) disclose for Jonathan Adam Feldschuh?

DAXOR CORP reported that Chief Scientific Officer Jonathan Adam Feldschuh received a grant of 25,000 shares of Daxor common stock. The award was recorded at $0.00 per share, indicating a compensation-related grant rather than an open-market purchase.

How many DAXOR CORP (DXR) shares does Jonathan Adam Feldschuh hold after this grant?

After the 25,000-share grant, Jonathan Adam Feldschuh holds 78,908 Daxor common shares directly. This total reflects his updated ownership position reported in the Form 4, including the newly granted stock award.

When do the newly granted DAXOR CORP (DXR) shares to Jonathan Feldschuh vest?

The 25,000 Daxor common shares granted to Jonathan Feldschuh vest on June 23, 2026. Vesting means the shares become fully earned and no longer subject to the grant’s vesting conditions on that date.

Was the DAXOR CORP (DXR) insider transaction an open-market buy or a stock grant?

The transaction was a stock grant, not an open-market buy. The Form 4 lists transaction code “A” for grant, award, or other acquisition, with a price per share of $0.00, consistent with a compensation-related equity award.

What does transaction code “A” mean in the DAXOR CORP (DXR) Form 4 filing?

Transaction code “A” in the DAXOR CORP Form 4 indicates a grant, award, or other acquisition of securities. In this case, it reflects a 25,000-share stock award granted to Chief Scientific Officer Jonathan Adam Feldschuh.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 05:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feldschuh Jonathan Adam

(Last) (First) (Middle)

109 MECO LANE

(Street)

OAK RIDGE TENNESSEE 37830

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DAXOR CORP [ DXR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Daxor Common Stock	06/23/2026		A		25,000(1)	A	$0	78,908	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 25,000 shares granted vest on June 23, 2026.

	/s/ Jonathan Feldschuh	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)